Antiviral activity of Bifidobacterium adolescentis SPM 0214 against herpes simplex virus type 1.
Herpes Simplex Virus type 1 (HSV-1) antibodies are found in up to 90 percent of the general population. About 30% of patients who have been exposed to HSV-1 develop recurrent infections, and this degree is continually increasing. In addition, resistance to all major anti-herpetic drugs such as acyclovir (ACV) has been increasingly reported. These observations underscore the importance of discovering new therapeutic tools for the treatment of HSV-1 infections. Bifidobacterium spp. has been studied in various fields including antibacterial and anticancer effect, but the antiviral activity was studied very little. The aim of this study was to test the antiviral activity of Bifidobacterium spp. against HSV-1. The Bifidobacterium adolescentis SPM 0214 used in this study through the screening of 23 Bifidobacterium spp. by plaque assay was assessed the cell viability assay in Vero cells. We also measured the plaque reduction assay and yield reduction assay after B. adolescentis SPM 0214 treatment at concentrations ranging between 10 and 10⁴ μg/mL. The B. adolescentis SPM 0214 was not toxic to Vero cells, and the inhibition of plaque and yield formation was obviously increased compared to those of the control (no additive). Therefore, these results indicate that antiviral activity of B. adolescentis SPM 0214 against HSV-1.
Department of Pharmacy, Sahmyook University, Seoul, 139-742, Korea.
Hyang Mi
HM
An
Do Kyung
DK
Lee
Jung Rae
JR
Kim
Si Won
SW
Lee
Min Kyeong
MK
Cha
Kang Oh
KO
Lee
Nam Joo
NJ
Ha
D000328:Adult; D000818:Animals; D000898:Antibiosis; D000998:Antiviral Agents / Q000627:therapeutic use; D001644:Bifidobacterium / Q000254:growth & development* / Q000302:isolation & purification; D002470:Cell Survival; D002522:Chlorocebus aethiops; D005243:Feces / Q000382:microbiology; D006561:Herpes Simplex / Q000517:prevention & control; D018259:Herpesvirus 1, Human / Q000254:growth & development* / Q000472:pathogenicity; D006801:Humans; D019936:Probiotics / Q000627:therapeutic use; D056910:Republic of Korea; D014709:Vero Cells; D010948:Viral Plaque Assay; D055815:Young Adult
D000998:Antiviral Agents